Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance with a 10% revenue increase and improved gross margins. The company has also raised its revenue guidance, indicating optimism about future growth. Despite risks and uncertainties mentioned, the financial health and growth prospects appear strong, suggesting a positive market reaction.
Key Financial Performance
Revenue Revenue for Q4 2025 was $150 million, representing a 10% increase year-over-year. This growth was driven by higher demand for our critical care products and expansion into new markets.
Gross Margin Gross margin improved to 55% in Q4 2025, up from 50% in Q4 2024. The improvement was attributed to cost efficiencies and favorable product mix.
Operating Expenses Operating expenses were $60 million in Q4 2025, a 5% increase year-over-year. The increase was primarily due to investments in R&D and marketing initiatives.
Net Income Net income for Q4 2025 was $20 million, compared to $15 million in Q4 2024, marking a 33% increase. This was driven by higher revenue and improved operational efficiency.
Cash Flow from Operations Cash flow from operations was $25 million in Q4 2025, up from $18 million in Q4 2024, a 39% increase. The improvement was due to better working capital management and higher profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Explicit Risks: Forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements.
Regulatory Risks: The company refers to its SEC filings, including annual and quarterly reports, for a detailed discussion of risk factors, implying potential regulatory and compliance challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-Looking Statements: Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Benjamin Haynor
CFO Clinical
Clinical Services
Director Heyburn
Director Yuan
Division Benjamin
Division EST
Division Jon
EST lady
Heyburn Co
Hickman Ladenburg
Inc Mathew
Jon Hickman
Ladenburg Thalmann
Mathew Schneider
Medical Inc
Melissa Tomkiel
Relations Melissa
Riley Securities
Schneider CFO
Securities Inc
Services VP
Services Vice
Strata Critical
Thalmann Co
VP Finance
Yuan Zhi
Zhi Riley
gentleman Strata
SRTA Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call summary shows strong financial performance with a 10% revenue increase and improved gross margins. The company has also raised its revenue guidance, indicating optimism about future growth. Despite risks and uncertainties mentioned, the financial health and growth prospects appear strong, suggesting a positive market reaction.
Strata Critical Medical, Inc. (SRTA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call highlights strong financial performance with record segment adjusted EBITDA and improved margins. The Q&A section reveals positive sentiment from analysts about growth potential, driven by new customer acquisition and market share gains. Despite some concerns about guidance clarity, the overall tone is optimistic, with expectations for continued growth and improved margins. The absence of debt and a healthy cash position further supports a positive outlook.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
